SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging alongside other semiconductor leaders as strong CPU performance data from Intel drives sector-wide momentum and investor FOMO. The community is actively debating whether this parabolic rally is a sustainable AI-driven breakout or an overextended bubble, with many traders focused on short squeezes and aggressive price action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to the company's expanding role in AI infrastructure, specifically following confirmation of orders linked to Marvell and potential integration into hyperscale ecosystems. The community is actively celebrating a significant short squeeze, with many long-term shareholders highlighting the company's move from R&D to commercial execution as a major long-term catalyst.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending as investors speculate on potential commercial catalysts tied to upcoming DRAM wafer results and ongoing collaborations with semiconductor equipment leaders like Applied Materials. The community is actively debating the company's valuation, the necessity of recent share authorization requests, and the long-awaited conversion of research and development engagements into definitive revenue-generating license agreements.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing an aggressive price re-rating fueled by stronger-than-expected data center and AI-driven CPU demand, which has spurred broad semiconductor sector momentum. While some community members are actively debating if the rally is a sustainable shift in demand or an overextended momentum squeeze, many are focused on the stock's historic volatility and breakout performance following recent earnings.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is experiencing significant volatility and downward pressure as shareholders react to a recent shelf offering and concerns over clinical trial timelines. While the community remains polarized, with some investors accumulating shares on dips anticipating future trial data and a potential short squeeze, others are expressing frustration over the persistent selling and lack of clear upward momentum.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and record-breaking momentum, with community debate centered on whether this surge represents a sustainable AI-driven growth cycle or a speculative bubble reminiscent of the dot-com era. Traders are actively discussing the extreme technical overextension and concentration of the trade, with many weighing the risks of a blow-off top against the potential for continued upside from data center demand.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently trending as retail investors react to a recent convertible notes offering, which triggered short-term volatility despite analysts viewing it as a move to strengthen the company's balance sheet for long-term R&D. The community remains deeply divided, with many long-term holders expressing frustration over price stagnation and leadership execution, while others highlight the company's $2 billion cash pile and upcoming clinical data catalysts as reasons to remain bullish.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) has captured significant community attention due to its historic streak of consecutive green sessions and parabolic price action, prompting intense debate over whether it represents a sustainable AI-driven bull run or an overdue blow-off top. Investors are actively discussing the risks of extreme overbought conditions while weighing tactical hedging strategies, such as using inverse ETFs, against a bullish narrative centered on unrelenting demand for AI infrastructure.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a sharp sell-off as investors react to margin concerns and geopolitical headwinds, despite the company beating revenue expectations and raising its AI-driven growth targets. Community sentiment is deeply divided between long-term investors viewing the pullback as a generational buying opportunity and traders expressing frustration over extreme volatility and the broader rotation of capital away from enterprise software.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as retail investors speculate that Founder Patrick Soon-Shiong's ongoing trip to Japan signals a significant upcoming international partnership or distribution deal. The community remains divided between long-term holders optimistic about global commercial expansion and vocal traders frustrated by persistent price volatility and recent legal headlines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


345oknetbr

345ok net br